Cofactor Genomics, San Francisco, a clinical RNA sequencing and translational assay developer, has launched an RNA-based immune profiling kit developed for laboratories seeking to derive the immune composition of tumor samples.The immune composition of a tumor is proving to be a valuable predictor of response to current immunotherapies and numerous drugs in development.

Cofactor’s ImmunoPrism immune profiling kit reports on the most impactful immune modulatory molecules demonstrated to have implications in drug discovery, biomarker development, and immunotherapy efficacy prediction. Speci?cally, ImmunoPrism details the quantitative percentage of eight major immune cell types and expression levels of ten immune escape genes. Building on data from thousands of RNA expression profiles, the fully analyzed, proprietary, biomarker discovery report includes quantitative immune cell characterizations and enables intra- and intersample immune cell ratios and comparisons, which have been shown to have prognostic value. The report also includes statistics such as p-value, threshold for patient selection, predictive accuracy, and positive/negative predictive values.

“Recent advancements in immunotherapies have resulted in more than 500 drug and combination clinical trials—significantly more trials than there are patients to fill them,” says Scott Kopetz, MD, PhD, FACP, of the division of cancer medicine at the MD Anderson Cancer Center. “Improved tools are needed to provide immune profiling of our tumors, with the goal to ultimately match the right patients with the right trials.”

Using the ImmunoPrism immune profiling kit, laboratories will have access to the same kit that Cofactor Genomics uses to prepare, sequence, and analyze tumor samples against the company’s database of machine-learning optimized immune reference expression models. Launch of the kit follows recent ImmunoPrism announcements about collaborations with the Fred Hutchinson Cancer Research Center and the National Cancer Institute, and, most recently, clinical accreditation of the assay within Cofactor’s lab by the College of American Pathologists.

“Cofactor Genomics’ ImmunoPrism kit provides scientists access to Cofactor’s innovation in RNA-based molecular immune profiling,” says Jarret Glasscock, PhD, founder and chief executive officer of Cofactor Genomics. “These are not single gene measurements to generate ambiguous estimates of enrichment. These are quantitative measures of specific immune cells in the sampled tumor microenvironment derived from Cofactor’s database of reference immune expression models. Our team’s decades of leadership in RNA profiling underscore Cofactor’s commitment to improving human health through the science of RNA.”

For further information, visit Cofactor Genomics.